Literature DB >> 24421447

Dexamethasone: idiopathic thrombocytopenic purpura in children and adolescents.

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@kumc.edu.

Entities:  

Year:  2013        PMID: 24421447      PMCID: PMC3839481          DOI: 10.1310/hpj4802-108

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  5 in total

Review 1.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

2.  Short-course high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in children.

Authors:  Dinesh Yadav; Jagdish Chandra; Sunita Sharma; Varinder Singh
Journal:  J Trop Pediatr       Date:  2010-04-13       Impact factor: 1.165

3.  A trial of high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in childhood.

Authors:  C Borgna-Pignatti; S Rugolotto; B Nobili; G Amendola; P De Stefano; R Maccario; F Locatelli
Journal:  J Pediatr       Date:  1997-01       Impact factor: 4.406

4.  Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura.

Authors:  Iris Hedlund-Treutiger; Jan-Inge Henter; Göran Elinder
Journal:  J Pediatr Hematol Oncol       Date:  2003-02       Impact factor: 1.289

Review 5.  International consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Roberto Stasi; Adrian C Newland; Victor S Blanchette; Paula Bolton-Maggs; James B Bussel; Beng H Chong; Douglas B Cines; Terry B Gernsheimer; Bertrand Godeau; John Grainger; Ian Greer; Beverley J Hunt; Paul A Imbach; Gordon Lyons; Robert McMillan; Francesco Rodeghiero; Miguel A Sanz; Michael Tarantino; Shirley Watson; Joan Young; David J Kuter
Journal:  Blood       Date:  2009-10-21       Impact factor: 22.113

  5 in total
  1 in total

1.  Evaluation of treatment plan by three-period pulses of high-dose dexamethasone among patients with primary immune thrombocytopenia on platelet count response and adverse events: A randomized Clinical trial.

Authors:  Alireza Sadeghi; Seyyideh Forough Hosseini; Saeid Rezaei Jouzdani
Journal:  J Res Med Sci       Date:  2020-09-30       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.